Last reviewed · How we verify

NCT03800576

Clinical Outcome of Liver Transplant Patients With Tacrolimus-based Immunosuppression

Completed Last updated 16 March 2021
What this trial tests

trial in Liver Transplantation in 113 participants. Completed in 22 September 2020.

Timeline
6 June 2019
Primary endpoint
8 October 2019
22 September 2020

Quick facts

Lead sponsorNational Taiwan University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment113
Start date6 June 2019
Primary completion8 October 2019
Estimated completion22 September 2020
Sites1 location across Taiwan

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 65, any sex, with Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Genetic polymorphism and numerous clinical factors could influence tacrolimus pharmacokinetics, which led to large inter-and intra-individual variability.Since its narrow therapeutic range,predicting therapeutic outcome and individualized dosage remains to be a challenge. The study's objective is to identify the genetic and clinical factors that can influence clinical outcome in liver transplant.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Liver Transplantation

Currently open trials in the same condition.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03800576.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing